首页> 美国卫生研究院文献>SAGE Open Medical Case Reports >Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
【2h】

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report

机译:患有侵袭性尿路上膀胱癌的患者患者术后未分化的尿路上皮癌的出现:案例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, the tumor disappeared. After 15 courses of the treatment, the tumor regrew. Pathological findings revealed invasive undifferentiated urothelial carcinoma consisting of relatively small tumor cells of the same size as lymphocytes, negative for neuroendocrine markers. Programmed death-ligand 1 expressions in tumor tissue changed from positive before treatment to negative after pembrolizumab treatment.
机译:一名83岁的男子接受了孕颅化疗,吉西他滨和顺铂治疗晚期膀胱癌。病理发现揭示了治疗前鳞状分化的侵袭性尿路上皮癌。经过七种疗法的彭布罗齐松治疗,肿瘤消失了。经过15次疗程的治疗,肿瘤重新重新进行。病理发现揭示了侵袭性未分化的尿路上皮癌,其肿瘤细胞与淋巴细胞相同的肿瘤细胞,神经内分泌标记的阴性。编程的死亡 - 配体1表达肿瘤组织中的表达从治疗前的阳性发生变化,在Pembrozumab治疗后对阴性进行阴性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号